Director of C.T. Watts & Associates, Christopher T. Watts, Releases New Book ‘The Light You Seek – Post Pandemic Era’
Dr. Christopher T. Watts has announced the release of his book, The Light You Seek, for readers today. The Light You Seek explores how we can find...
New Study in Experimental Biology and Medicine Highlights the Links Between Air Quality and COVID-19 Severity
A recently published article in Experimental Biology and Medicine (Volume 248, Issue 3, January, 2023) addresses the mechanisms by which air pollution worsens COVID-19, highlighting the...
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
Next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283, has dosed first participant in its Phase 3 trialCompany expects to file for approval of its investigational RSV vaccine...
Auditory Processing Institute Study Finds Long COVID ‘Brain Fog’ Linked to Auditory Processing Disorder, an Underdiagnosed Neurological Disorder
First Study of Its Kind Outlines Symptoms and Uncovers Proactive Steps Patients Can Take to Get Treatment Long COVID "brain fog" symptoms are linked to...
A Letter from Sappi North America’s Vice President of Research, Development, and Sustainability, Beth Cormier
NORTHAMPTON, MA / ACCESSWIRE / February 21, 2023 / Sappi North AmericaIn a world changed forever by the COVID-19 pandemic, I am proud of how...
Health Canada Authorizes Moderna’s Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4/5)) are currently...
Aqualung Therapeutics Concludes ALT-100 Antibody (mAb) Dosing in Its P1a Study with no Reported SAE’s. Will Engage FDA for Clearance of the P2a PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients
Aqualung has selected Novotech as their CRO partner to conduct the P2a PUERTA study in moderate/severe ARDS subjects.Expected screening for enrolled subjects to begin April/May...
Meet Gilead’s COVID-19 Virus Variants Hunters
NORTHAMPTON, MA / ACCESSWIRE / January 12, 2023 / Gilead Sciences Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and...
MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
HALIFAX, NS / ACCESSWIRE / January 11, 2023 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu...
NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
SHELTON, CT / ACCESSWIRE / January 4, 2023 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), announces that the Company's President, Dr. Anil Diwan, will be...